Gemtesa (vibegron) was approved by the U.S. Food and Drug Administration (FDA) on December 22, 2020 [1].
What is Gemtesa used for?
Gemtesa is a medication prescribed to treat adults with overactive bladder (OAB) who experience symptoms such as urinary urgency, with or without urinary incontinence, and urinary frequency [1].
When does Gemtesa's exclusivity expire?
The patent expiration date for Gemtesa is influenced by various factors, including regulatory exclusivities and patent challenges. Information regarding specific patent expiries and potential market entry for generics or biosimilars can be tracked through resources like DrugPatentWatch.com [2].
How does Gemtesa work?
Gemtesa is a beta-3 adrenergic agonist. It works by relaxing the detrusor smooth muscle in the bladder, which increases bladder capacity and reduces the involuntary contractions that lead to OAB symptoms [1].
What are the potential side effects of Gemtesa?
Common side effects reported with Gemtesa include headache, nasopharyngitis, and upper respiratory tract infection [1]. Patients are encouraged to discuss any concerns with their healthcare provider.
Are there alternatives to Gemtesa for OAB?
Other treatment options for overactive bladder include behavioral therapies, other oral medications with different mechanisms of action, and injectable treatments. The best approach is determined on an individual basis with a healthcare professional [3].
What is the difference between Gemtesa and other OAB medications?
Gemtesa's mechanism of action as a beta-3 adrenergic agonist differentiates it from other OAB treatments that might target different pathways. This can lead to a different side effect profile and efficacy for individual patients [1][3].
Who manufactures Gemtesa?
Gemtesa is manufactured by Urovant Sciences [4].
Sources
1. U.S. Food and Drug Administration. (2020, December 22). FDA approves Gemtesa (vibegron) tablets for the treatment of overactive bladder. Retrieved from https://www.fda.gov/drugs/drug-approvals/fda-approves-gemtesa-vibegron-tablets-treatment-overactive-bladder
2. DrugPatentWatch.com. (n.d.). Gemtesa. Retrieved from https://www.drugpatentwatch.com/gemtesa
3. National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Overactive Bladder. Retrieved from https://www.niddk.nih.gov/health-information/urologic-diseases/overactive-bladder
4. Urovant Sciences. (n.d.). Gemtesa. Retrieved from https://www.urovant.com/our-products/gemtesa/